120511-73-1 Anastrozole AKSci J10596
 
 
Loading Please Wait...
  J10596    AKSci Reference Standard
Anastrozole, 99% (HPLC), powder
 
2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1, 3-phenylene]bis(2-methyl-propiononitrile
Arimidex
a,a,a',a'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile
IDENTITY
CAS Number:120511-73-1
MDL Number:MFCD00866298
MF:C17H19N5
MW:293.37
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:99% (HPLC), powder
Spectra:NMR, FT-IR, GCMS, GC
Physical Form:White to off-white crystalline powder
Melting Point:80-86°C
Flash Point:238°C
Long-Term Storage:Store at room temperature
HAZARDOUS MATERIALS INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:DMSO: 40mg/mL; H2O: <1mg/mL; EtOH: 59mg/mL
Application(s):Aromatase inhibitor
Form:Free Base

REVIEW
 Anastrozole selectively inhibits aromatase. The principal source of circulating estrogen (primarily estradiol) is conversion of adrenally-generated androstenedione to estrone by aromatase in peripheral tissues. Therefore, aromatase inhibition leads to a decrease in serum and tumor concentration of estrogen, leading to a decreased tumor mass or delayed progression of tumor growth in some women. Anastrozole has no detectable effect on synthesis of adrenal corticosteroids, aldosterone, and thyroid hormone.

REFERENCES
[1]Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005 Jan 1-7;365(9453):60-2.
[2] Mauras N, Bishop K, Merinbaum D, Emeribe U, Agbo F, Lowe E: Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. J Clin Endocrinol Metab. 2009 Aug;94(8):2975-8. Epub 2009 May 26.
[3] Nabholtz JM: Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention. Oncology. 2006;70(1):1-12. Epub 2006 Jan 26.
[4] Milani M, Jha G, Potter DA: Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women. Clin Med Ther. 2009 Mar 31;1:141-156.

GHS

Pictograms

Signal Word
Danger

Hazard Statements
H302; H360

Precautionary Statements
P201; P202; P264; P270; P281; P301+P312; P308+P313; P330; P405; P501

Current as of April 23, 2021

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS

For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.


CATEGORIES
 APIs and Bioactives > Aromatose inhibitors


PubChem